{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:26Z","timestamp":1789770326069,"version":"4.0.1"},"reference-count":139,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>The advent of chimeric antigen receptor (CAR)-T cells has recently changed the prognosis of relapsing\/refractory diffuse large B-cell lymphomas, showing response rates as high as 60 to 80%. Common toxicities reported in the pivotal clinical trials include the cytokine release syndrome (CRS) and the Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), a stereotyped encephalopathy related to myeloid cell activation and blood\u2013brain barrier dysfunction, presenting with a distinctive cascade of dysgraphia, aphasia, disorientation, attention deficits, vigilance impairment, motor symptoms, seizures, and diffuse brain oedema. The tremendous oncological efficacy of CAR-T cells observed in systemic B-cell malignancies is leading to their growing use in patients with primary or secondary central nervous system (CNS) lymphomas and in patients with solid tumours, including several CNS cancers. Early studies conducted in adult and paediatric patients with solid CNS tumours reported a distinct profile of neurotoxicity referred to as Tumour inflammation-associated neurotoxicity (TIAN), corresponding to local inflammation at the tumour site manifesting with focal neurological deficits or mechanical complications (e.g., obstructive hydrocephalus). The present review summarises available data on the efficacy and safety of CAR-T cells for solid and haematological CNS malignancies, emphasising known and emerging phenotypes, ongoing challenges, and future perspectives.<\/jats:p>","DOI":"10.3390\/brainsci14121220","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T05:43:43Z","timestamp":1733118223000},"page":"1220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-7447","authenticated-orcid":false,"given":"Leonardo","family":"Palazzo","sequence":"first","affiliation":[{"name":"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pieri","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-9058","authenticated-orcid":false,"given":"Giulia","family":"Berzero","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Faculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy"},{"name":"Neurorehabilitation Unit, Neurophysiology Unit, Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: Application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing CAR T cell therapy through the use of multidimensional omics data","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): Current status and future perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e166028","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-22-2293","article-title":"Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"216355","DOI":"10.1016\/j.canlet.2023.216355","article-title":"Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers","volume":"572","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2019.08.014","article-title":"Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer","volume":"77","author":"Gorchakov","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: An interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, L., Oill, A.T., Blanchard, M., Wu, M., Hibbard, J., Sepulveda, S., Peter, L., Kilpatrick, J., Munoz, M., and Stiller, T. (2023). Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R\u303f2-targeting CAR T cells: An interim analysis. Res. Sq.","DOI":"10.21203\/rs.3.rs-3454977\/v1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: A phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: A phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Durgin, J.S., Henderson, F., Nasrallah, M.P., Mohan, S., Wang, S., Lacey, S.F., Melenhorst, J.J., Desai, A.S., Lee, J.Y.K., and Maus, M.V. (2021). Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.669071"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-024-04564-y","article-title":"Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide","volume":"166","author":"Fadul","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1002\/cti2.1137","article-title":"Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma","volume":"Volume 9","author":"Tang","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lin, Q., Ba, T., Ho, J., Chen, D., Cheng, Y., Wang, L., Xu, G., Xu, L., Zhou, Y., and Wei, Y. (2021). First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients with Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.694941"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e006365","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: Laboratory tools for an early and differential diagnosis","volume":"11","author":"Ventosa","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: A French multicentre cohort","volume":"14","author":"Couturier","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"ref_63","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref_64","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2024, October 03). Washington, DC: US Department of Health and Human Services, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bastos-Oreiro, M., Gutierrez, A., Reguera, J.L., Iacoboni, G., L\u00f3pez-Corral, L., Terol, M.J., Ort\u00edz-Maldonado, V., Sanz, J., Guerra-Dominguez, L., and Bailen, R. (2022). Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO\/GETH Spanish Groups. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.855730"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO)\u2014A tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Meng, J., Wu, X., Sun, Z., Xun, R., Liu, M., Hu, R., and Huang, J. (2021). Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.698607"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gust, J., Ponce, R., Liles, W.C., Garden, G.A., and Turtle, C.J. (2020). Cytokines in CAR T Cell-Associated Neurotoxicity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.577027"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1148\/radiol.2021210760","article-title":"Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy","volume":"302","author":"Smith","year":"2022","journal-title":"Radiology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1097\/HS9.0000000000000533","article-title":"Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells","volume":"5","author":"Karschnia","year":"2021","journal-title":"Hemasphere"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"Bonda","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.21873\/anticanres.15876","article-title":"Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome","volume":"42","author":"Asawa","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Katsin, M., Shman, T., Migas, A., Lutskovich, D., Serada, Y., Khalankova, Y., Kostina, Y., and Dubovik, S. (2024). Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1380451"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","article-title":"CAR T cell therapies for diffuse midline glioma","volume":"9","author":"Thomas","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: A phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: The clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/ajh.27316","article-title":"CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network","volume":"99","author":"Choquet","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/WNL.0000000000200608","article-title":"Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells","volume":"98","author":"Karschnia","year":"2022","journal-title":"Neurology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: Comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?","volume":"56","author":"Ghafouri","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: A GLA\/DRST study","volume":"7","author":"Ayuk","year":"2023","journal-title":"Blood Adv."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2021.249","article-title":"CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma","volume":"33","author":"Liu","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2900310","DOI":"10.1155\/2022\/2900310","article-title":"The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed\/Refractory Central Nervous System B-Cell Lymphoma","volume":"2022","author":"Xue","year":"2022","journal-title":"J. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Zhang, H., Yan, Z., Wang, Y., Qi, Y., Hu, Y., Li, P., Cao, J., Zhang, M., Xiao, X., and Shi, M. (2022). Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.965224"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: A multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CJI.0000000000000416","article-title":"Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and\/or HIV: A Multicenter Experience","volume":"45","author":"Yuen","year":"2022","journal-title":"J. Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: A meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-023-03619-9","article-title":"Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells","volume":"73","author":"Kline","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Genoud, V., and Migliorini, D. (2023). Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1108297"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and Other Primary Brain Malignancies in Adults: A Review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Rodriguez, S.M.B., Kamel, A., Ciubotaru, G.V., Onose, G., Sevastre, A.S., Sfredel, V., Danoiu, S., Dricu, A., and Tataranu, L.G. (2023). An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311110"},{"key":"ref_112","first-page":"985","article-title":"Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas","volume":"5","author":"Debinski","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/mt.2012.210","article-title":"T cells redirected to EphA2 for the immunotherapy of glioblastoma","volume":"21","author":"Chow","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","article-title":"HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors","volume":"16","author":"Ahmed","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/14653249.2012.666633","article-title":"Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor \u03b12 chain in recurrent malignant glioma patients with HLA-A*24\/A*02 allele","volume":"14","author":"Iwami","year":"2012","journal-title":"Cytotherapy"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Rao, P., Furst, L., Meyran, D., Mayoh, C., Neeson, P.J., Terry, R., Khuong-Quang, D.A., Mantamadiotis, T., and Ekert, P.G. (2022). Advances in CAR T cell immunotherapy for paediatric brain tumours. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.873722"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00234-010-0802-6","article-title":"MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: A pilot study","volume":"53","author":"Vrabec","year":"2011","journal-title":"Neuroradiology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-023-04324-4","article-title":"Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model","volume":"163","author":"Chawla","year":"2023","journal-title":"J. Neurooncol."},{"key":"ref_121","first-page":"vdad135","article-title":"Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity","volume":"5","author":"Stoecklein","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Li, A.Y., and Iv, M. (2022). Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging. Front. Radiol., 2.","DOI":"10.3389\/fradi.2022.883293"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"111093","DOI":"10.1016\/j.intimp.2023.111093","article-title":"Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer","volume":"125","author":"Sayadmanesh","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Tey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Hotblack, A., Kokalaki, E.K., Palton, M.J., Cheung, G.W., Williams, I.P., Manzoor, S., Grothier, T.I., Piapi, A., Fiaccadori, V., and Wawrzyniecka, P. (2021). Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-01418-9"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"eaay9209","DOI":"10.1126\/sciadv.aay9209","article-title":"Engineering light-controllable CAR T cells for cancer immunotherapy","volume":"6","author":"Huang","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of CAR-T cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1093\/brain\/awad195","article-title":"The coming of age of liquid biopsy in neuro-oncology","volume":"146","author":"Berzero","year":"2023","journal-title":"Brain"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ubieto, A., Mart\u00edn-Mu\u00f1oz, A., Poza, M., Dorado, S., Garc\u00eda-Ortiz, A., Revilla, E., Sarandeses, P., Ruiz-Heredia, Y., Baumann, T., and Rodr\u00edguez, A. (2023). Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1243241"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e007329","DOI":"10.1136\/jitc-2023-007329","article-title":"Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy","volume":"12","author":"Shishido","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/12\/1220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:43:57Z","timestamp":1760114637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/12\/1220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":139,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["brainsci14121220"],"URL":"https:\/\/doi.org\/10.3390\/brainsci14121220","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}